# To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids

> **NCT01041911** · PHASE2 · COMPLETED · sponsor: **Panacea Biotec Ltd** · enrollment: 102 (actual)

## Conditions studied

- Hemorrhoids

## Interventions

- **DRUG:** Euphorbia tablets
- **DRUG:** Euphorbia tablets
- **DRUG:** Euphorbia tablets
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT01041911
- **Lead sponsor:** Panacea Biotec Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-10
- **Final completion:** 2010-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2012-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01041911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01041911, "To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01041911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*